KYYWF yields 0.10% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, KYYWF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KYYWF + PFE for your $10,000?
Keywords Studios plc provides integrated outsourced creative and technical services to the video game industry. The company offers art creation services related to the production of graphical art assets for inclusion in the video game, including concept art creation, as well as 2D and 3D art asset production and animation. It also provides marketing services, which include game trailers, marketing art and materials, PR, and brand campaign services; and audio/voice-over services, including script translation, actor selection, and talent management through pre-production, audio direction, recording, and post-production, as well as offers music licensing or music soundtracks selling services. In addition, the company offers localization services related to translation and cultural adaptation of in-game text and audio scripts in various game platforms and genres; and localization testing services consisting of testing the linguistic correctness and cultural acceptability of computer games. Further, it provides functional testing services related to quality assurance services provided to game producers to ensure game functions. Additionally, the company provides player support services related to the live operations support, such as community management, player support, and associated services to producers of games, as well as software engineering services for developing video games. It serves game developers and publishers. The company operates in Canada, the United States, the United Kingdom, Italy, Russia, Japan, Poland, China, India, Ireland, the Philippines, Spain, France, Singapore, Australia, and internationally. Keywords Studios plc was founded in 1998 and is headquartered in Dublin, Ireland.
Full KYYWF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.